Fulcrum Therapeutics Inc (FULC) Stock Price, Quote & News

Company Profile

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers drug targets for potential treatment inherited aplastic anemias, such...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 651 8851

Website: www.fulcrumtx.com

Address:

26 Landsdowne Street, Cambridge, United States

RunnerSignals Nov. 13 at 9:24 PM

today market warriors $IRWD $NESR $FULC $ASH $CNDT opened red but charged back green by the close

0 · Reply

dogDazeSummer Oct. 31 at 7:19 PM

$RANI RA Capital announces 9.9% position last night and that alone is good for 40% (was 100% earlier) Bodes well for $IFRX $RYTM $FULC $TSHA

0 · Reply

anachartanalyst Oct. 30 at 2:02 PM

$FULC https://anachart.com/wp-content/uploads/ana_temp/1761832937_soc-img.jpg

0 · Reply

_www_larval_com_ Oct. 29 at 6:17 PM

$FULC just sunk -3% lower to -14% (~1Mv) a few minutes ago, 11/21 options, follow for more volatility.

0 · Reply

biochirp Oct. 29 at 5:55 PM

$FULC will get this 10% back in a week

0 · Reply

d_risk Oct. 29 at 5:16 PM

$FULC - Fulcrum Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors FULC’s 10-Q risk factors now detail major operating losses, heavy R&D spend, urgent future capital needs, and reliance on external funding; highlight the Phase 3 losmapimod failure, narrowed pipeline, and workforce cuts; expand on clinical, regulatory, IP, and manufacturing hurdles; and add new risks on market acceptance, pricing, reimbursement, third-party reliance, global expansion, and evolving compliance and data privacy laws. #Biotechnology #RegulatoryCompliance #FinancialRisk #ClinicalTrialRisk #PharmaceuticalR&D 🟢 Added 🟠 Removed https://d-risk.ai/FULC/10-Q/2025-10-29

0 · Reply

McLarkin Oct. 29 at 4:33 PM

$FULC good earnings call, good decision I made to buy in, not the best decision for me to buy in the first 30 mins of trading tho....but hey.. I had to go out...

0 · Reply

biochirp Oct. 29 at 2:16 PM

$FULC $GSK discontined their SCD drug today; number of oral SCD assets available is dwindling

0 · Reply

JJnewly18 Oct. 29 at 11:27 AM

$FULC going to 15 today just watch and see

0 · Reply

DonCorleone77 Oct. 29 at 11:27 AM

$FULC Fulcrum Therapeutics reports Q3 EPS (31c), consensus (29c)

0 · Reply

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 3, 2025, 4:45 PM EST - 13 days ago

Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting

Oct 29, 2025, 2:56 PM EDT - 18 days ago

Fulcrum Therapeutics, Inc. (FULC) Q3 2025 Earnings Call Transcript

Oct 29, 2025, 7:00 AM EDT - 18 days ago

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025

Oct 22, 2025, 8:54 AM EDT - 25 days ago

Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET

Aug 26, 2025, 8:00 AM EDT - 2 months ago

Fulcrum Therapeutics to Present at Upcoming Investor Meetings

Jul 29, 2025, 6:48 AM EDT - 3 months ago

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025

Jul 29, 2025, 6:45 AM EDT - 3 months ago

Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

Jul 28, 2025, 4:01 PM EDT - 3 months ago

Fulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

May 29, 2025, 4:10 PM EDT - 6 months ago

Fulcrum Therapeutics to Present at Upcoming Medical Meetings

May 29, 2025, 8:30 AM EDT - 6 months ago

Fulcrum Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

May 8, 2025, 4:05 PM EDT - 6 months ago

Fulcrum Therapeutics to Participate in Upcoming May Conferences

May 1, 2025, 1:55 PM EDT - 7 months ago

Fulcrum Therapeutics, Inc. (FULC) Q1 2025 Earnings Call Transcript

May 1, 2025, 7:00 AM EDT - 7 months ago

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025

Apr 24, 2025, 8:00 AM EDT - 7 months ago

Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET

Mar 4, 2025, 4:05 PM EST - 9 months ago

Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference

Feb 25, 2025, 10:58 PM EST - 9 months ago

Fulcrum Therapeutics, Inc. (FULC) Q4 2024 Earnings Call Transcript

Feb 25, 2025, 7:00 AM EST - 9 months ago

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024

Feb 18, 2025, 4:05 PM EST - 9 months ago

Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast on Tuesday, February 25, 2025, at 8:00 a.m. ET

Feb 6, 2025, 4:05 PM EST - 10 months ago

Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Nov 26, 2024, 4:05 PM EST - 1 year ago

Fulcrum Therapeutics to Participate in Upcoming December Conferences

Nov 13, 2024, 7:48 PM EST - 1 year ago

Fulcrum Therapeutics, Inc. (FULC) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 4:05 PM EST - 1 year ago

Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference

Nov 6, 2024, 8:00 AM EST - 1 year ago

Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET

Oct 7, 2024, 2:03 PM EDT - 1 year ago

FMR LLC's Strategic Reduction in Fulcrum Therapeutics Inc Shares

Oct 2, 2024, 6:30 PM EDT - 1 year ago

Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Fulcrum Therapeutics Inc For Possible Securities Fraud

Oct 1, 2024, 6:15 PM EDT - 1 year ago

Fulcrum Therapeutics, Inc. Is Being Investigated For Violating Securities Laws And The Schall Law Firm Urges Shareholder Participation

Sep 30, 2024, 8:00 PM EDT - 1 year ago

Investors Are Encouraged To Join The Schall Law Firm In An Inquiry Into Fulcrum Therapeutics Inc For Possible Securities Fraud

Sep 28, 2024, 8:00 PM EDT - 1 year ago

The Schall Law Firm Is Looking Into Whether Fulcrum Therapeutics Inc Committed Securities Fraud And Impacted Investors Should Reach Out

Sep 27, 2024, 6:30 PM EDT - 1 year ago

Shareholders Are Encouraged To Join The Schall Law Firm's Inquiry Into Fulcrum Therapeutics, Inc. For Violating Securities Laws

Sep 27, 2024, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Fulcrum Therapeutics, Inc. (FULC) And Encourages Shareholders to Reach Out

Sep 26, 2024, 6:40 PM EDT - 1 year ago

Fulcrum Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Investors To Lend A Hand

Sep 26, 2024, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulcrum Therapeutics, Inc. (FULC) and Encourages Shareholders to Learn More About the Investigation

RunnerSignals Nov. 13 at 9:24 PM

today market warriors $IRWD $NESR $FULC $ASH $CNDT opened red but charged back green by the close

0 · Reply

dogDazeSummer Oct. 31 at 7:19 PM

$RANI RA Capital announces 9.9% position last night and that alone is good for 40% (was 100% earlier) Bodes well for $IFRX $RYTM $FULC $TSHA

0 · Reply

anachartanalyst Oct. 30 at 2:02 PM

$FULC https://anachart.com/wp-content/uploads/ana_temp/1761832937_soc-img.jpg

0 · Reply

_www_larval_com_ Oct. 29 at 6:17 PM

$FULC just sunk -3% lower to -14% (~1Mv) a few minutes ago, 11/21 options, follow for more volatility.

0 · Reply

biochirp Oct. 29 at 5:55 PM

$FULC will get this 10% back in a week

0 · Reply

d_risk Oct. 29 at 5:16 PM

0 · Reply

McLarkin Oct. 29 at 4:33 PM

$FULC good earnings call, good decision I made to buy in, not the best decision for me to buy in the first 30 mins of trading tho....but hey.. I had to go out...

0 · Reply

biochirp Oct. 29 at 2:16 PM

$FULC $GSK discontined their SCD drug today; number of oral SCD assets available is dwindling

0 · Reply

JJnewly18 Oct. 29 at 11:27 AM

$FULC going to 15 today just watch and see

0 · Reply

DonCorleone77 Oct. 29 at 11:27 AM

$FULC Fulcrum Therapeutics reports Q3 EPS (31c), consensus (29c)

0 · Reply

biochirp Oct. 28 at 7:48 PM

$FULC woah volume today

0 · Reply

JarvisFlow Oct. 20 at 11:55 AM

HC Wainwright & Co. has adjusted their stance on Fulcrum Therapeutics ( $FULC ), setting the rating to Buy with a target price of 12.

0 · Reply

biochirp Oct. 15 at 5:43 PM

$FULC $PTGX leak good for JNJ circling back here to get a bolt on deal done?

1 · Reply

biochirp Oct. 8 at 5:33 PM

$FULC cant stop wont stop

0 · Reply

Kai506 Oct. 7 at 7:13 PM

$FULC This took much longer and adding on small dips, but eventually turned out to be a decent swing. Good luck longs.

0 · Reply

AnomalyDetective Oct. 3 at 12:23 PM

#SPX $SPY S&P 500 Momentum Gauges in the longest positive weekly signal since 2020. Negative MG values are rising: http://vmbreakouts.com Active ETF portfolio +52.3% YTD with $GDXU +220.9% $LABU +45.3% and my forecast articles are available here: https://seekingalpha.com/article/4820291-total-return-breakouts-biotechs-accelerating-to-overtake-gold-rush MDA Breakout picks up +250.9% YTD in average cumulative weekly returns led by $CTMX $FULC picks this week and all new Week 41 MDA picks have been released for members: https://seekingalpha.com/mp/1201-value-momentum-breakouts/ Free breakout samples at: http://top.vmbreakouts.com

0 · Reply

AnomalyDetective Oct. 2 at 4:08 PM

Our $ONDS prior mda breakout pick continues in strong positive MDA breakout conditions along with many other http://top.vmbreakouts.com prior selections. Follow the signals for the best results. Week 40 MDA picks extending the count to 340 weeks with at least one pick gaining over 10%: $CTMX $FULC for members. Now up over +248% YTD with all new Week 41 MDA breakout picks out after the close at: https://seekingalpha.com/mp/1201-value-momentum-breakouts ⚠️Major indices $QQQ $SPY #SPX hitting new highs led by #Tech #Gold #Biotech but watch the signals for any market changes live: http://vmbreakouts.com

0 · Reply

Quantumup Oct. 1 at 2:41 PM

Oppenheimer reiterated $FULC at an Outperform rating and a $15 price target: $XBI $AGIO $NVS $VRTX Oppenheimer said: We've been getting questions on how updated pociredir data later this year will impact FULC shares. For us, the readout is more "icing on the cake," rather than major binary because we already thought pociredir looked like a drug at the lower 12 mg dose. Absent any idiosyncratic toxicity or material weakening of efficacy, shares should continue to grind higher. However, given Fulcrum's recent run (shares are up 80% YTD vs. the XBI ahead 9%), it's fair to assume that the buyside's internal bar may be higher than our own. Based on our field work, that bar appears to be a 10% or higher HbF improvement. We believe that's achievable based on prior healthy volunteer data.

0 · Reply

biochirp Oct. 1 at 2:38 PM

$FULC Global blood therapeutics got bought for 5.4B, they had a marketed drug (now pulled from market) and 2nd in PH2. So, once FULC clears PH1 with good data .. lets a market cap >1B

0 · Reply

biochirp Sep. 26 at 3:45 PM

$FULC wants to clear 10

0 · Reply

PKlee Sep. 26 at 2:45 PM

$FULC what’s going on here?? Sudden jump??

0 · Reply

Chingying Sep. 25 at 8:14 PM

$FULC What’s causing the epic run up ? I like the run up though. Data for higher dosage 20mg trial coming out by 12/31/2025.

0 · Reply

Market Cap	468.12M
Revenue (ttm)	80.00M
Net Income (ttm)	-9.73M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-12.16%
Debt to Equity Ratio	0.00

Volume	474,100
Avg Vol	579,118
Day's Range	N/A - N/A
Shares Out	54.12M
Stochastic %K	78%
Beta	3.02
Analysts	Strong Sell
Price Target	$13.88